Efficacy and Safety of Gonadotropin-Releasing Hormone Agonist Treatment to Suppress Puberty in Gender Dysphoric Adolescents

Journal of Sexual Medicine

Volumn 13, Issue 7, 2016, Pages 1125-1132

  Schagen, Sebastian E E ^a,b   Cohen Kettenis, Peggy T ^a   Delemarre van de Waal, Henriette A ^a,b   Hannema, Sabine E ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gender Dysphoria; Gonadotropin Releasing Hormone Agonist; Gonadotropins; Puberty Suppression; Sex Steroids

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; SEX HORMONE; TRIPTORELIN; GONADORELIN; GONADOTROPIN;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMALE GENITAL TRACT PARAMETERS; GENDER DYSPHORIA; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT PARAMETERS; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBERTY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; PHOTON ABSORPTIOMETRY; PUBERTY, PRECOCIOUS; SEXUAL MATURATION; TRANSSEXUALISM;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; FEMALE; GONADAL STEROID HORMONES; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; MALE; PUBERTY; PUBERTY, PRECOCIOUS; SEXUAL MATURATION; TRANSSEXUALISM;

EID: 84974575076     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1016/j.jsxm.2016.05.004     Document Type: Article

References (29)

1. Aitken M., Steensma T.D., Blanchard R., et al. Evidence for an altered sex ratio in clinic-referred adolescents with gender dysphoria. J Sex Med 2015, 12:756-763.
2. Steensma T.D., Kreukels B.P., de Vries A.L., et al. Gender identity development in adolescence. Horm Behav 2013, 64:288-297.
3. Hembree W.C., Cohen-Kettenis P., Delemarre-van de Waal H.A., et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009, 94:3132-3154.
4. de Vries A.L., Steensma T.D., Doreleijers T.A., et al. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med 2011, 8:2276-2283.
5. Delemarre-van de Waal H.A., Cohen-Kettenis P.T. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol 2006, 155:S131-S137.
6. Carel J.C., Eugster E.A., Rogol A., et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009, 123:e752-e762.
7. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC. 4th ed, text rev.
8. Marshall W.A., Tanner J.M. Growth and physiological development during adolescence. Annu Rev Med 1968, 19:283-300.
9. Tanner J.M. Growth at adolescence 1962, Blackwell, Oxford. 2nd ed.
10. Schonbeck Y., Talma H., van D.P., et al. The world's tallest nation has stopped growing taller: the height of Dutch children from 1955 to 2009. Pediatr Res 2013, 73:371-377.
11. Cole T.J., Bellizzi M.C., Flegal K.M., et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000, 320:1240-1243.
12. Grinspon R.P., Andreone L., Bedecarras P., et al. Male central precocious puberty: serum profile of anti-Mullerian hormone and inhibin B before, during, and after treatment with GnRH analogue. Int J Endocrinol 2013, 2013:823064.
13. Manasco P.K., Pescovitz O.H., Feuillan P.P., et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988, 67:368-372.
14. Behre H.M., Nashan D., Hubert W., et al. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 1992, 74:84-90.
15. Freire A.V., Gryngarten M.G., Ballerini M.G., et al. Assessment of estradiol response after depot triptorelin administration in girls with central precocious puberty. Horm Res Paediatr 2016, 85:58-64.
16. Saggese G., Federico G., Barsanti S., et al. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study. J Clin Endocrinol Metab 2001, 86:1900-1904.
17. DiMartino-Nardi J., Wu R., Fishman K., et al. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty. J Clin Endocrinol Metab 1991, 73:902-906.
18. Potau N., Ibanez L., Sentis M., et al. Sexual dimorphism in the maturation of the pituitary-gonadal axis, assessed by GnRH agonist challenge. Eur J Endocrinol 1999, 141:27-34.
19. Tack L.J., Craen M., Dhondt K., et al. Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis. Biol Sex Differ 2016, 7:14.
20. Khatchadourian K., Amed S., Metzger D.L. Clinical management of youth with gender dysphoria in Vancouver. J Pediatr 2014, 164:906-911.
21. Klink D., Caris M., Heijboer A., et al. Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab 2015, 100:E270-E275.
22. Shea K.L., Gavin K.M., Melanson E.L., et al. Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment. Menopause 2015, 22:1045-1052.
23. Santosa S., Bonnes S.L., Jensen M.D. Acute female hypogonadism alters adipose tissue fatty acid storage factors and chylomicronemia. J Clin Endocrinol Metab 2016, 101:2089-2098.
24. Dumesic D.A., Abbott D.H., Eisner J.R., et al. Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women. Fertil Steril 1998, 70:94-101.
25. Finkelstein J.S., Lee H., Burnett-Bowie S.A., et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013, 369:1011-1022.
26. Magiakou M.A., Manousaki D., Papadaki M., et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010, 95:109-117.
27. Lem A.J., van der Kaay D.C., Hokken-Koelega A.C. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment. J Clin Endocrinol Metab 2013, 98:77-86.
28. Tuchman S., Thayu M., Shults J., et al. Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease. J Pediatr 2008, 153:484-490.
29. Staphorsius A.S., Kreukels B.P., Cohen-Kettenis P.T., et al. Puberty suppression and executive functioning: An fMRI-study in adolescents with gender dysphoria. Psychoneuroendocrinology 2015, 56:190-199.